Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2015 Dec 18;16(3):152–162. doi: 10.1016/j.clml.2015.12.003

Table 6.

Responses (expressed in percentage) to dasatinib or nilotinib by pre-existing organ function

Response Dasatinib*
N=107		 Nilotinib*
N=108		 Overall
N=215		 P
Normal
N=89		 Liver
N=13		 Renal
N=6		 Normal
N=91		 Liver
N=9		 Renal
N=9		 Normal
N=180		 Liver
N=22		 Renal
N=15		 Normal vs. Liver Normal vs. Renal
BCR-ABL/ABL ratio on the international scale at 3 months
<10% 78 77 100 87 89 89 82 82 93 0.963 0.474
Cumulative response within 1 year, %
CCyR 91 100 100 93 78 78 92 91 87 0.830 0.354
MMR 74 77 83 84 67 56 79 73 67 0.518 0.278
MR4.5 35 39 50 43 22 22 39 32 33 0.644 0.659
Best cumulative response, %
CCyR 92 100 100 93 78 78 93 91 87 0.670 0.324
MMR 78 85 83 76 67 67 86 86 80 1.000 0.472
MR4.5 70 69 83 68 56 44 69 64 60 0.617 0.565
*

One patient in each cohort had both renal and liver dysfunction.

Abbreviations: MR 4.5, molecular response with 4.5 log reduction on the international scale; MMR, major molecular response; CCyR, complete cytogenetic response; CHR, complete hematologic response.